Do you have a question or suggestion?

Fill out the form and we will contact you as soon as possible. Thank you for your interest!

     

     

    Main Contacts  Pro EuroDILINet

    General enquiries: info@proeurodilinet.eu


    Dr Raul ANDRADE
    Chair

    Prof Guruprasad AITHAL
    Vice Chair

    Dr Rossella MAGLI
    Science officer

    Ms Nathalie WARENGHIEN
    Administrative officer

    Working groups

    WG1. IN-DEPTH PHENOTYPING IN DILI
    Leader: Prof. Helena Cortez-Pinto. University of Lisboa (Portugal) 

    Deputy Leader: Dr. Michael Manns. Hannover Medical School (Germany)
    Co-Leader: Jane Grove (PhD.) (UK)

    AIM To support translational research in DILI and will integrate and collaborate closely with the remaining WGs.
    TASK DILI case definition, characterization and classification of phenotypic sub-groups
    DELIVERABLES
    • Standardized approach to diagnosis and SOPs for data/samples collection (year 1)
    • Pre-funded database of DILI patients (year 1-4)
    • Review: DILI diagnosis & management (year 2)
    • Classification system for HDS (year 3)
    • Consensus on nomenclature, diagnosis, classification, assessment & treatment of DILI (year 3-4)

     

    Deliverables WG1 2018 2019 2020 2021 2022
    Standardized approach to diagnosis and SOPs for data/samples collection
    Pre-funded database of DILI patients
    Review: DILI diagnosis & management
    Classification system for HDS
    Consensus on nomenclature, diagnosis, classification, assessment & treatment of DILI
    WG2. DILI RISK STRATIFICATION
    Leader: Prof. Gerd A Kullak Ublick. University Hospital Zurich (Switzerland)
    Deputy Leader: Dr. Michael Merz. University Hospital Zurich (Switzerland)

    Co-leader: Prof. Ann Daly. Newcastle University (United Kingdom)
    Co- Leader as sustitute: Dr. Dean Naisbitt. Biosketch University of Liverpool (United Kingdom)

    AIM To characterize drug’s potential for hepatotoxicity, individual susceptibility, and their interactions
    TASK Evaluate the risk of DILI, assess its severity and predict its outcomes
    DELIVERABLES
    • EU Framework translational research plan for biomarker development (year 1-2)
    • Scientific publication on the current knowledge DILI risk modifiers (year 2)
    • Written input to commercial enterprises for Future Market Exploitation of biomarkers (year 3)
    • Publication on predictive models of drug hepatotoxicity (year 4)

     

    Deliverables WG2 2018 2019 2020 2021 2022
    EU Framework translational research plan for biomarker development
    Scientific publication on the current knowledge DILI risk modifiers
    Written input to commercial enterprises for Future Market Exploitation of biomarkers
    Publication on predictive models of drug hepatotoxicity
    WG3. PRECLINICAL EVALUATION OF DILI
    Leader:  Prof. José Fernández Checa, Institute of Biomedical Research, Barcelona, Spain.
    Co- Leader: Leonard J Nelson, PhD. Institute for Bioengineering
    AIM To contribute to an improved regulatory decision-making concerning DILI.
    TASK To review the current knowledge and expertise on preclinical methods and technologies that assess the associated risk of DILI of a given drug.
    DELIVERABLES
    • Review: Realistic in vitro/in silico models in hepatotoxicity; non-invasive optical/ chemical imaging techniques (year 2)
    • List appropriate control compounds for testing new in vitro models (year 3-4)
    • Roadmap for the development of preclinical models of DILI (year 3-4)

     

    Deliverables WG3 2018 2019 2020 2021 2022
    Review: Realistic in vitro/in silico models in hepatotoxicity; non-invasive optical/ chemical imaging techniques
    List appropriate control compounds for testing new in vitro models
    Roadmap for the development of preclinical models of DILI

     

    WG4. DESIGN AND ENDPOINTS IN CLINICAL DILI INVESTIGATIONS
    AND TRIALS
    Leader: Prof. Einar Stefán Björnsson, Chiefof the Internal Medicine at the Landspitali University hospital Reykjavik Iceland. 

    Co- Leader:  Dr Mercedes Robles Díaz, University Hospital Virgen de la Victoria , Málaga Spain.
    Co- Leader: Dr Judith Sanabria Cabrera, University Hospital Virgen de la Victoria, Málaga Spain

    AIM To set standards for clinical trials design and establish precise endpoints to assess the efficacy of novel interventions or for exploring novel biomarkers in DILI.
    To share individual data from clinical trials from the drugs under development as wel as post-marketing where DILI has been identified as an issue.
    TASK Define criteria and establish endpoints to measure efficacy on novel interventions in DILI
    DELIVERABLES
    • Design of clinical trials to assess the effect of an intervention on DILI course or outcomes (year 1-4)
    • SOPs to facilitate the conduct of a multicentre clinical trial in DILI (year 2-4)
    • Study design for biomarkers evaluation & robust statistical methods (year 2-3)

     

    Deliverables WG4 2018 2019 2020 2021 2022
    SOPs to facilitate the conduct of a multicentre clinical trial in DILI
    Study design for biomarkers evaluation & robust statistical methods
    Design of clinical trials to assess the effect of an intervention on DILI course or outcomes
    WG5. KNOWLEDGE DISSEMINATION, COMMUNICATION,
    TRAINING PLAN AND EXTERNAL RELATIONSHIPS WITH STAKEHOLDERS
    Leader: Dr Simona Stankevičiūtė, Hospital of Lithuanian University of Health Sciences (Lithuania). 

    Co-leader: Dr Thomas Hammond, Molecular and Systems Toxicology, University of Basel, Switzerland.

    AIM Development of good practice models to disseminate the knowledge gained throughout the Action.
    TASK To monitor and evaluate the dissemination plan and advise the Core Group if the approach needs changing.
    DELIVERABLES
    • Website setup, social media & updates (year 1-4)
    • Quality plan and good practice policies (year 1)
    • Mobile application development & update (year 2-4)
    • Mid-term review of the COST Action proposal (year 2)
    • Preparation of large-scale European projects (year 2-4)
    • RoadMap to DILI research in Europe (year 4)

     

    Deliverables WG5 2018 2019 2020 2021 2022
    Website setup, social media & updates
    Quality plan and good practice policies
    Mobile application development & update
    Mid-term review of the COST Action Proposal
    Preparation of large-scale European projects
    RoadMap to DILI research in Europe